Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

“While macro headlines/tweets continue to dictate stock performance, and we expect volatility to continue, we see biotech ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

they have a significant influence over the performance of the biotech sector as a whole. While investors may not be able to capitalize on the catalysts that "made or broke" these companies in Q1 ...

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.

Medicamen Biotech, operating in the Pharmaceuticals sector and classified as a Smallcap ... a low of ₹377 and a high of ₹630. In terms of performance, Medicamen Biotech has shown a return ...

The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...

LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers through a biotech industry ...